

Neurotrope

09:08 11 Feb 2016

Neurotrope candidate in bid to treat Alzheimer's

Neurotrope (OTCMKTS:NTRP) revealed first patients have been dosed in its phase 2b clinical trial of lead candidate Bryostatin-1 for advanced Alzheimer's disease. The company expects to report three month interim data during the first quarter of 2017 with complete six month data set expected during the first half of 2017. Charles S. Ramat, Neurotrope president and chief executive, told investors: "We believe that Bryostatin represents a new and disruptive technology in what has been an unsuccessful war against Alzheimer's disease. "This trial seeks to statistically verify preliminary results seen in compassionate use patients and patients treated in our completed Phase 2a study," "We are excited at being on the cusp of providing a meaningful treatment to this suffering, severely impaired population and their caregivers." The Bryostatin-1 Phase 2b trial is an ongoing randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability and efficacy of the drug in the treatment of patients suffering from moderately severe to severe Alzheimer's. The study plans to enroll 150 patients at 30 US sites. It will evaluate two different doses of Bryostatin (20 or 40µg) versus placebo, with a total of seven doses administered over 12 weeks. A second randomization will take place after the first 12 weeks of treatment, with patients in the Bryostatin arms to receive either a different dose of Bryostatin or the same dose. Patients in the placebo arm will be randomized to receive either Bryostatin (10µg) or placebo. Shares added 2.5%..

Price: US\$7.06

Market Cap: US\$91.23M

1 Year Share Price Graph



Share Information

Code: NTRP

Listing: NASDAQ

52 week	High	Low
	\$11.90	\$3.34

Sector: Pharma & Biotech

Website: www.neurotropebioscience.com

Company Synopsis:

Neurotrope operates as a clinical-stage biopharmaceutical and diagnostics company. Its two product platforms include a minimally-invasive diagnostic test for Alzheimer's disease and a drug candidate, known as bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any

specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.